Revive · GHRH Analog
Tesamorelin 10MG
A synthetic GHRH analog — stimulates natural growth hormone release with particular effect on visceral fat.
85,00 €
10 mg vial
In stock
Requires AA water for reconstitution
Per reference20units
Cadence5× per week
Dose1mg
Vial10mg / 2 mL
About
A stabilised GHRH analog — the same receptor action as Sermorelin, with a stronger signal.
Research describes Tesamorelin as particularly effective at reducing visceral adipose tissue through elevated endogenous GH and IGF-1. Literature notes improvements in lipid profiles, insulin sensitivity, cognitive support, and GH-related anti-aging markers.
Sequence lists Tesamorelin under the Revive category - sleep, recovery, growth hormone.
Vial content
10 mg lyophilised Tesamorelin in an glass vial. Reconstitution requires 5% AA water mixed with the BAC water, with a ratio of 5:95 — Tesamorelin precipitates in neutral bacteriostatic water.
After reconstitution with 0.1 mL AA water and 1.9 mL BAC water, concentration is ~5 mg/mL. At reference, 20 units on a U-50 insulin syringe draws approximately 1 mg. Rotate between abdominal quadrants, outer thighs, and upper arms.
Storage: refrigerated 2–8°C after reconstitution. Do not freeze.
Reported effectsWhat the literature
What the literature
describes.
Improved lipid & insulin markers
Lean muscle preservation
Energy & endurance
Cognitive support
Reported timelineWhat the literature
What the literature
reports, by phase.
Week 1–2
01
Week 1–2 — Improved sleep, appetite regulation, and morning steadiness.
Week 3–6
02
Week 3–6 — Early visceral fat changes. Reported firmer abdominal tone and clearer energy.
Week 6–12
03
Week 6–12 — Consolidation of body-composition change. Lipid profile and insulin sensitivity trends.
Long-term
04
Long-term — Retained baseline improvements after cycling. Sustained GH rhythm support.
Reference dosing
Reference profile.
Baseline
Standard10units / injection
1MG · 5× per week (Monday–Friday)
- Injection siteSubcutaneous · abdomen, thigh, upper arm
- RotationQuadrant cycle, avoid repeat sites
- TimingFasted; Evening - aligns with nighttime GH rhythm | Mornings when on GLP1
Recommended cycle
Three months on. One month off. Up to three cycles annually.
Cycling preserves pituitary responsiveness. The off-phase restores receptor sensitivity after a sustained GH signal.
Vial details
| Content | Tesamorelin · lyophilised |
| Mass | 10 mg |
| Reconstitution | 2 mL water |
| Concentration | ~5 mg/mL |
| Reconstitution | 5% AA water |
| Supply (baseline) | ~2 weeks per vial |
| Storage | 2–8°C · do not freeze |
Mechanism
GHRH signal. Visceral priority.
Tesamorelin binds GHRH receptors in the anterior pituitary, stimulating endogenous growth hormone production and subsequently raising IGF-1. The pathway preferentially drives lipolysis in visceral adipose depots.
Effects compound through nighttime GH rhythms - sleep, recovery, and body composition shift in parallel.
- ReceptorGHRH receptors in the anterior pituitary.
- GH releasePulsatile endogenous growth hormone output.
- IGF-1Downstream elevation supports muscle preservation and metabolism.
- Visceral lipolysisPreferential reduction of abdominal adipose tissue.
Safety signalsReported side effects
Reported side effects
& contraindications.
Reported side effects
- Injection-site redness or mild discomfort
- Vivid dreams or temporary water retention
- Mild joint discomfort or tingling
- Rare GI discomfort or injection-site irritation
Contraindications
- Active malignancy
- Pregnancy or breastfeeding
- Known peptide or excipient hypersensitivity
Severe swelling, fever above 38°C, worsening fatigue, rash, dizziness, hives, breathing difficulty, or facial swelling - discontinue and contact a clinician.
Watch it done properly.
Reconstitution, site rotation, storage — on video.